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e.2013.06Abstract Due to the signiﬁcant boost in community expenditure with health topics, mainly regard-
ing drugs, numerous countries, have already put into operation, or are in the process of arguing the
adoption of actions to guarantee the excellence of health care provided to the population. One of
the less risky strategies-is the adoption of economic procedures applied to health, more speciﬁcally,
pharmaco-economics analysis.
This paper aims to contribute to the dissemination of notions and techniques of economic study
with a view to integrate these into strategy decisions of payment rationalization and the search
for clinical effectiveness. It includes a literature review covering the category of expenses and reim-
bursement in health issues, the methodologies of pharmaco-economics revision, cost-minimization,
cost-beneﬁts, cost-effectiveness and cost-utility analysis, as well as its main characteristics, advan-
tages, disadvantages and applicability.
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that associates clinical concepts of efﬁcacy, safety and quality
of various procedures in health care, with measures of eco-
nomic cost.1 A second, more speciﬁc deﬁnition is: ‘Phar-
maco-economics is the description and analysis of the costs
of drug therapy to health care system and society.2 Also, it
could be deﬁned as an ‘‘application of economic theory to
pharmacotherapy’’ or ‘‘economic evaluation of drugs’’ or, it
could be placed at the interface between two large traditional
areas, health and economy.3
It is a tool that helps to select more efﬁcient options (with a
good cost/effect relationship) and could help in the distribu-
tion of health resources in a more just and balanced manner.
Pharmaco-economics contributes to the rational use of medi-
cines by incorporating cost to questions on safety, efﬁcacy
and quality of different medical therapies, and to the search
for a better relationship between costs and results. While mak-
ing use of the word ‘‘pharmaco’’ (drug) in its nomenclature, it
presents tools that can be equally utilized for the consideration
of medicines, health programs and even of governmental
schemes, provided that the characteristics inherent to each
application are observed.4 In representing an area of intersec-
tion, ‘‘conﬂicts’’ are obvious due to the diverse forms on how
health is measured. Conventionally, the professions associated
to the health area are centered on distinctive ethics, according
to which health has no price and a life saved justiﬁes all at-
tempts. Then again, the economy is under joined by the ethic
of common safety or public ethics. The origin of these differ-
ences resides in the attitudes of each group regarding resource
utilization, but both have a vision for the future that incorpo-
rates resource rationalization and improved care rendered in
health issues.5 Countries that have invested in the training
and specialization of human resources to act at the econ-
omy/health interface have achieved higher rationalization rates
in the process of management and quality of health services.6–82. How the government handles this good/cost effect relationship
Management of the health/illness course has required ever
higher amount of incomes especially those spent for medicines,
caused by different variables. Included in these variables are
the development of new technologies, efforts to increase access
to health systems, strategies for the promotion of new medi-
cines directed at both the prescribing and the consumingclasses and also population aging and the consequent rise in
chronic-degenerative diseases.5
In general, increases in public expenses with pharmaceuti-
cals, tend to be higher than inﬂation or increases in Gross
Domestic Product – GDP, leading to apprehension among
governments.6,9
In this context, worldwide countries adapted different phar-
maco-economics methods, for their health care policies, in or-
der to be less damaging for their GDP.
The cost of defending U.S. malpractice claims is estimated
at $6.5 billion in 2001, only 0.46% of total health spending.
The two most important reasons for higher U.S. spending ap-
pear to be higher incomes and higher medical care prices.10 In
the USA, health expenses surpassed 1.3 trillion dollars in 2000,
reaching 2 trillion in 2006, a value equivalent to 16% of the
GDP. According to projections, this percentage is set to in-
crease to 20% by 2015.10
In the United Kingdom, the growth in health expenses is
higher than in other sectors of the economy, although the
NICE politics applied on healthcare system. In 2001 and
2002, expenses with health represented 17% of public expendi-
ture, the greatest proportion since 1948.11,12,10 Italy, has im-
posed since 1997 an economic analysis within the pricing and
reimbursement of pharmaceuticals, although, this country is
not beneﬁting from the best decisional process using phar-
maco-economics measures.13,14The total expenditure with
medicines increased 11% in 2005, reaching 24.8 billion dol-
lars.15 In the face of ampliﬁed operating cost and the need of
at least preserving the value of health services, governments
will be obliged to implement supporting ﬁnancial measures
including tax hikes, cut backs in other areas and charging con-
sumers.16 Medical drugs consume a considerable portion of the
country’s resources, having a strong impact on overall health
expenses.16
Adopting these less damaging strategies, such as the eco-
nomic analysis during the process of choosing higher priority
alternatives can supply information, helping managers com-
pare alternatives and decide about the best option for their
program needs, in a bid to associate rationalization of ex-
penses to clinical efﬁciency. Clinical efﬁciency means maximal
attention to quality and user satisfaction, with the least possi-
ble social costs.17
A lot of countries developed lately the politics on pharma-
economics. For instance in Turkey, medical curriculums are
being developed in a multidisciplinary approach focused on
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come country, the direct cost of care per patient with breast
cancer was estimated from $1451.35 to $1615.29; in Algeria19
there are government attempts to reduce the drug price (Alge-
ria is part of the Top Fifteen Developing Countries list with
the Highest Pharmaceutical Tariffs). The mean (SD) family
size of household respondents from Saudi Arabia was 6.60
(3.20) members, with 0.32% reporting no medicines present
in the household, 81.8% of households reporting ﬁve or more
medicines, and 29.9% of respondents reporting having at least
10 medications at home. When analyzed on the basis of total
medication cost, medication wastage was 19.2% and 25.0%
in Saudi Arabia and other Gulf countries, respectively. The
mean out-of-pocket expenditure (based on the percentage of
annual income) for medications was 0.72% for households in
Saudi Arabia compared with 0.48% in other Gulf countries.
Families in Saudi Arabia and other Gulf countries spent a to-
tal of US $150 million on medications that were never con-
sumed. However, there appear to be no immediate solutions
to the problem of medication wastage’s impact on health care
costs20
The association of quality and user satisfaction with the
lowest possible social costs demarks the clinical efﬁciency on
economical strategies. This tool helps on implementing the
health care cost, but this tool does not bring an immediate
solution to the problem of wastage‘s impact.21,22 As other
authors23, we think that the use of generic alternatives should
be promoted in the national level, in order to attempt an alle-
viation of the costs on pharmaceuticals,
3. Types of pharmaco-economics evaluation
3.1. Cost minimization analysis
Cost Minimization Analysis (CMA), one of the simplest
economic evaluations, is utilized when the result of two or
more interventions is the same in terms of their clinical conse-
quences. In CMA, only costs are submitted for comparison,
because the efﬁcacy or effectiveness of comparable alternatives
is equal.12 This approach is justiﬁed when alternatives of
comparable programs or therapies produce clinically equiva-
lent results, as in taking decision on pharmotherapeutic
guides.24 For instance, it may be applied in the process of
developing pharmacotherapeutic guidelines, for two or more
products with proven equivalence in safety and efﬁcacy. Thus,
the ﬁrst critical step prior to conducting a CMA is to deter-
mine the therapeutic equivalence of the interventions. When
intervention results differ, it is not possible to proceed to cost
minimization analysis. An example of CMA is the analysis of
administration costs of the same medicine given using different
routes of administration.9 But again this example is not valid
in all cases (for instance one route may be used for emergency
situations or to initiate treatment, while the other may be more
appropriate for maintenance of treatment).
3.2. Cost beneﬁt analysis (CBA)
Cost Beneﬁt Analysis (CBA) establishes the relationship
between costs associated to treatment and ﬁnancial beneﬁts
generated by it. All cost (investments) and beneﬁts (conse-
quences) of alternatives are measured in monetary terms sothat it will be possible to verify whether the beneﬁts exceed
the expenses for each intervention.25 Among other aspects,
the return of applied resources in a health issue may be com-
pared with gains obtained by investments made in other areas
of the economy.26 Examples: (i) the relationship of treatment
costs and the economy of resources resulting from shorter pa-
tient hospital stay; (ii) the costs of a vaccination program and
the resources yielded by the reduction of absence from work or
the number of hospital admissions; (iii) the costs of a program
of early treatment of diseases versus delayed treatment or its
complications etc. The results of cost-beneﬁt analysis are pres-
ent in the form of liquid beneﬁts, that is, beneﬁts of the inter-
vention minus the costs of intervention.27 This type of
instrument evaluates the economic viability of social projects,
it can be applied to a given program or to various alternative
ones in order to compare them in terms of their ‘‘social proﬁt-
ability’.27 This presumes the concept of programs in the social
area (health, education etc.) as investments in human capital,
in the sense that these programs, whether for empowering or
rendering the work force healthier or increasing their produc-
tivity, boost the productivity of the economic system as a
whole.28 The theoretical basis of this technical instrument
therefore becomes evident: the theory of human capital and
the methodology of the economic analysis of investments.29
Thus, these studies show the theoretical advantages of facil-
itating choices between health and non-health programs (for
example, between subsidizing a new drug and increasing funds
for school transportation), and of providing subsidies to public
administrators and to society for taking better informed deci-
sions and enabling the optimization of resource utilization.
This type of analysis has the inherent inconvenience of the
difﬁculty attributing monetary value to the results and to life,
not permitting simultaneous comparisons of products with
more than one indication.30 Intangible beneﬁts, such as the
subjective health expression of each patient and the value of
human life, are obviously very difﬁcult to be expressed in mon-
etary terms. Furthermore, the evaluation of beneﬁts to persons
that do not have an economic activity becomes impaired.31
This type of analysis has often been criticized for ignoring
important beneﬁts resulting from health programs and for
concentrating on items of easy measurement. Initially, it was
the most used analysis, but due to the difﬁculty of attributing
monetary values to human life, cost-effectiveness is currently
more utilized.323.3. Cost effectiveness analysis (CEA)
Cost Effectiveness Analysis (CEA)33 concerns the relationship
between the cost of a treatment, measured in monetary units,
and its clinical beneﬁts (effectiveness) to the patient. Results
are expressed in non monetary units, that is, in terms of im-
proved health or natural units (lengthened life span, number
of lives saved, clinical cures, and days free of symptoms or
pain, cost/hour of nursing time, cost/mercury millimeter of al-
tered arterial blood pressure).34 Thus, the unit of measurement
selected will depend on the objective of the program or treat-
ment evaluated.35
In general terms, CEA is the most appropriate technique
when the choice has to be made between two or more compet-
ing options, for which the gains expected in health can be ex-
pressed in terms of a measuring common effect.36 Therefore,
4 A. Musaraj et al.CEA is always comparative and considered in the choice of the
best strategy to attain the same objective. Examples include the
relationship between costs of treatment by different antihyper-
tensive agents and the respective degrees of effectiveness in
decreasing the patient’s arterial pressure, or costs of different
chemotherapy treatments against cancer and their respective
degrees of effectiveness in saving or extending lives.37
CEA represents the type of analysis most utilized in phar-
maco-economics, because it enables to use, in daily practice,
the same units utilized in clinical assays.
The calculation of the cost-effectiveness ratio expresses the
additional cost required to reach an extra unit of clinical ben-
eﬁt and is expressed by the difference between the cost of two
interventions, divided by the difference between their conse-
quences in terms of health (effectiveness).38
Another measurement unit of cost-effectiveness is the qual-
ity of life related to health (QLRH).39 The two major types of
QLRH are: (a) those which are speciﬁcally named, formulated
to evaluate improvements in the quality of life produced by a
speciﬁc treatment; and (b) those generically named, developed
to evaluate variations in life quality produced by any type of
intervention.40
However, in several studies that work with effects (such as
the number of deaths prevented) and not with products (vacci-
nation, number of houses attended with sewers, etc.) this
restriction may be effectively overcome in the sense that strat-
egies of intervention are compared with totally distinct prod-
ucts (expansion of the health system, immunization,
maternal-infant care, for example).413.4. Cost utility analysis (CUA)
Cost Utility Analysis (CUA)2 considers the relationship be-
tween costs of a treatment and its beneﬁts to the health-related
quality of life of the patient (utility), as well as the risks of ad-
verse drug reactions. This method combines patient satisfac-
tion and preference with cost-effectiveness analysis.42 It is
applicable in studies aimed at comparing different treatments
mainly targeted to chronic patients. Examples include relation-
ship between the cost of different cancer treatments and their
respective life quality indexes, related to patient health during
the extra years that they have gained; cost for a rheumatoid
arthritis treatment and the health-related quality of life the pa-
tient started to lead following pain reduction and improved
mobility.43 However, it does not allow comparisons between
different sectors, for example, health costs in relation to
education.
In Cost Utility Analysis, cost to obtain ‘‘one year of healthy
life’’ is calculated with different treatments that is, it incorpo-
rates the amount and also the quality of life in the years thatwere
saved by means of a treatment. The results (output) are ex-
pressed as the cost for the ‘‘years of healthy life’’ or ‘‘years of life
adjusted for quality ‘‘(QALY – quality-adjusted life-years).
QALYs are calculated by the years of life gained, multiplied
by a quality index, veriﬁed bymeans of speciﬁc questionnaires.44
Modern medicine is concerned about the improvement of life
quality and not only about longevity of life.45
The use of life expectancy adjusted for quality enables the
evaluation of situations in which there is increased survival un-
der health conditions that are not perfect or therapies that do
not alter survival, but improve quality of life.46CUA is presently the economic evaluation approach pre-
ferred by specialists, mainly because it allows the comparison
of different programs or treatments without the ethical prob-
lems occurring in CBA over attributing monetary values to
health.47 The use of lists of treatments and health programs
classiﬁed according to their cost per QALY, has helped the
setting of priorities in health issues.48 The lower cost treat-
ments per QALY should be implemented ﬁrst, and those with
higher cost per QALY should be considered of lesser priority.
However, although useful, this cannot be the sole criterion em-
ployed in the setting up of health priorities.49
Thus, pharmaco-economics analysis considers the eco-
nomic factors in the utilization of medicines, but does not
exclude clinical and humanistic results as important subjects
for evaluation. The real value of an intervention or policy
can only be found when all dimensions of the result are mea-
sured and taken into consideration.50 Viewed in this manner,
the economic criterion cannot perform the major role.
4. Sensitivity analysis
Sensitivity analysis51 takes into account the uncertainties com-
mon to economic evaluations of health, since the results found
in clinical practice can vary in relation to results reported in the
medical literature. Thus, this type of analysis recalculates the
cost-effectiveness ratios obtained, modifying one or more
parameters of the study.52 Examples of variables are the degree
of effectiveness of the intervention, the natural course of the
disease, the costs related to the treatment, the expected result
in life quality, among others.
The Panel of Cost-Effectiveness in health recommends the
use of this technique in economic health evaluations and sug-
gests the calculation of all parameters or variables of the model
whose estimation is not precise or whose values may vary in dif-
ferent settings.53 Sensitivity analysis can be conducted modify-
ing one or numerous variables of the model simultaneously.54
If, on varying the values of a given parameter the chosen
strategy remains stable, one states that the model is insensitive
to this parameter and the lack of precision in its estimate does
not decrease the validity of the conclusions obtained by the
model.55
In developed countries, as Albania, cost analysis is fre-
quently employed for managers to gain adequate information
when deﬁning and choosing priority interventions in the health
area.56–58
Therefore, it is important that the government and health
systems become involved with the spreading of concepts and
techniques of economic analysis59, investing in the education
and training of qualiﬁed human resources60 and stimulating
the production of studies applying these tools, both in public
and private sectors, and actually start to incorporate economic
analysis into policy decisions on health issues.61
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